ATE399179T1 - Zusammensetzungen und verfahren für wt1- spezifische immunotherapie - Google Patents

Zusammensetzungen und verfahren für wt1- spezifische immunotherapie

Info

Publication number
ATE399179T1
ATE399179T1 AT99951690T AT99951690T ATE399179T1 AT E399179 T1 ATE399179 T1 AT E399179T1 AT 99951690 T AT99951690 T AT 99951690T AT 99951690 T AT99951690 T AT 99951690T AT E399179 T1 ATE399179 T1 AT E399179T1
Authority
AT
Austria
Prior art keywords
compositions
methods
specific immunotherapy
immunotherapy
specific
Prior art date
Application number
AT99951690T
Other languages
German (de)
English (en)
Inventor
Alexander Gaiger
Martin Cheever
Original Assignee
Corixa Corp
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corp, Alexander Gaiger filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE399179T1 publication Critical patent/ATE399179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99951690T 1998-09-30 1999-09-30 Zusammensetzungen und verfahren für wt1- spezifische immunotherapie ATE399179T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
ATE399179T1 true ATE399179T1 (de) 2008-07-15

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99951690T ATE399179T1 (de) 1998-09-30 1999-09-30 Zusammensetzungen und verfahren für wt1- spezifische immunotherapie

Country Status (25)

Country Link
EP (1) EP1117687B1 (enExample)
JP (3) JP4243792B2 (enExample)
KR (1) KR100752065B1 (enExample)
CN (1) CN100486995C (enExample)
AR (1) AR021849A1 (enExample)
AT (1) ATE399179T1 (enExample)
AU (1) AU6407899A (enExample)
BR (1) BR9914116A (enExample)
CA (1) CA2349442C (enExample)
CZ (1) CZ20011144A3 (enExample)
DE (1) DE69938970D1 (enExample)
ES (1) ES2310052T3 (enExample)
HK (1) HK1039782B (enExample)
HU (1) HUP0103598A3 (enExample)
IL (2) IL142216A0 (enExample)
MX (1) MXPA01003344A (enExample)
MY (1) MY139226A (enExample)
NO (1) NO325839B1 (enExample)
NZ (1) NZ510600A (enExample)
PL (1) PL201881B1 (enExample)
RU (1) RU2237674C2 (enExample)
SA (1) SA00200872B1 (enExample)
TR (1) TR200101482T2 (enExample)
TW (1) TWI285648B (enExample)
WO (1) WO2000018795A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3728439B2 (ja) 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
JP4229832B2 (ja) * 2001-06-29 2009-02-25 忠範 真弓 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
JP4480580B2 (ja) 2002-09-20 2010-06-16 株式会社癌免疫研究所 Ｗｔ１置換型ペプチド
KR20120054644A (ko) 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
ATE538809T1 (de) 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
CA2544214C (en) 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
CN105315347A (zh) 2005-11-30 2016-02-10 株式会社癌免疫研究所 新型肽化合物
EP2385117B1 (en) * 2006-02-22 2016-07-27 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
KR101454287B1 (ko) * 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
EP2980219B1 (en) * 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
EP2119778B1 (en) * 2007-02-27 2015-11-04 International Institute of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
JP5596980B2 (ja) * 2007-02-28 2014-10-01 アメリカ合衆国 ブラキュリポリペプチドおよび使用方法
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
JPWO2009066462A1 (ja) * 2007-11-20 2011-04-07 日本電気株式会社 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
RU2010127298A (ru) * 2007-12-05 2012-01-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) Вакцинная композиция против злокачественной опухоли
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP3611270B1 (en) * 2009-05-19 2021-12-01 University Of Miami Kits for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
EP2626418B8 (en) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
AU2012236068A1 (en) * 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
AU2012276908A1 (en) 2011-06-28 2014-02-20 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
ES2805337T3 (es) 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CA2912514A1 (en) * 2013-05-13 2014-11-20 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
WO2015129790A1 (ja) 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
EP3231438B1 (en) * 2014-12-11 2020-06-17 International Institute of Cancer Immunology, Inc. Wt1 immunotherapy for intraocular angiogenic disease
AU2016320877A1 (en) * 2015-09-10 2018-04-19 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by T cell therapy
CA3005896C (en) * 2015-11-20 2025-09-23 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY MEANS OF THE COMBINATION OF A WT1 PEPTIDE AND A CHECKPOINT INHIBITOR
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
EP3725327A3 (en) * 2017-04-10 2021-01-20 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
WO2019122052A2 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3182959A1 (en) 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
KR20240046880A (ko) 2021-08-12 2024-04-11 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암을 처치 또는 예방하기 위한 의약 조성물 및 방법
CN118076378A (zh) * 2021-09-24 2024-05-24 株式会社车疫苗研究所 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007509A1 (en) * 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
CA2337743C (en) * 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1

Also Published As

Publication number Publication date
BR9914116A (pt) 2002-01-15
MXPA01003344A (es) 2004-04-21
KR20010085861A (ko) 2001-09-07
SA00200872B1 (ar) 2007-01-30
PL201881B1 (pl) 2009-05-29
CA2349442C (en) 2012-12-04
JP2007001984A (ja) 2007-01-11
TW200606176A (en) 2006-02-16
AR021849A1 (es) 2002-08-07
TR200101482T2 (tr) 2002-01-21
WO2000018795A9 (en) 2000-08-31
WO2000018795A3 (en) 2000-10-26
HUP0103598A2 (hu) 2002-01-28
HK1039782A1 (en) 2002-05-10
MY139226A (en) 2009-08-28
EP1117687B1 (en) 2008-06-25
HUP0103598A3 (en) 2005-11-28
NO325839B1 (no) 2008-07-28
JP4243792B2 (ja) 2009-03-25
CZ20011144A3 (cs) 2002-06-12
TWI285648B (en) 2007-08-21
RU2237674C2 (ru) 2004-10-10
NO20011613D0 (no) 2001-03-29
IL142216A (en) 2009-06-15
AU6407899A (en) 2000-04-17
JP4235984B2 (ja) 2009-03-11
DE69938970D1 (de) 2008-08-07
CN100486995C (zh) 2009-05-13
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
PL348595A1 (en) 2002-06-03
JP2008069172A (ja) 2008-03-27
CA2349442A1 (en) 2000-04-06
KR100752065B1 (ko) 2007-08-28
CN1336935A (zh) 2002-02-20
EP1117687A2 (en) 2001-07-25
NO20011613L (no) 2001-05-29
IL142216A0 (en) 2002-03-10
NZ510600A (en) 2003-12-19
WO2000018795A2 (en) 2000-04-06
JP2002525099A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
ATE399179T1 (de) Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
DE69930964D1 (de) Zusammensetzungen und verfahren für mukosale abgabe
ATE288278T1 (de) Verfahren und zusammensetzungen zur peptidsynthese
DE60003250D1 (de) Reinigungszusammensetzungen und Verfahren zur Reinigung
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
ATE389417T1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
DE69723439D1 (de) Display und verfahren für digitaloszilloskop
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
DE69913056D1 (de) Schlickerzusammensetzungen für Diffusionsbeschichtungen
ATE277621T1 (de) Verfahren und zusammensetzungen zur prävention von toleranz von bronchodilatoren
DE69727328D1 (de) System für Raumklangeffekt und Verfahren dafür
DE69517683D1 (de) Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe
DE69915803D1 (de) Universelle zusatzstoffe für bohrlochzemente und verfahren
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE
DE69739776D1 (de) Verfahren zum Empfangen und Empfänger für OFDM-Signale
DE69811824D1 (de) SiC-Einkristall und Verfahren zu seiner Herstellung
DE60019627D1 (de) Ferrofluid-zusammensetzung und verfahren
ATE271598T1 (de) Desinfektionszusammensetzungen und verfahren
DE59802238D1 (de) Verfahren und giesseinrichtung für feinguss
DE69939331D1 (de) Wasserhärtbare zusammensetzungen für schienen und stützen
DE60121896D1 (de) Verfahren und System zum Mischen von Silikonzusammensetzungen
DE69919340D1 (de) Überzugszusammensetzungen und verfahren
DE60023461D1 (de) Verdichter und verfahren zur schmierung des kompressors
DE69727689D1 (de) Zusammensetzung für und verfahren zur metallverformung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties